This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • A Ph II/III seamless, multi-center, randomized, do...
Clinical trial

A Ph II/III seamless, multi-center, randomized, double-blind, placebo-controlled study of the reduction in signs and symptoms and inhibition of structural damage during treatment with tocilizumab versus placebo in patients with ankylosing spondylitis who

Read time: 1 mins
Last updated:9th Aug 2010
To assess the: efficacy of treatment with TCZ 4 mg/kg and 8 mg/kg versus placebo in AS patients who are na�ve to treatment with TNF antagonist therapy with regard to the proportion of patients who achieve an ASAS20 response at week 12 (confirmation at week 24) and the safety of TCZ 4 mg/kg and 8 mg/kg versus placebo with regard to AEs and laboratory assessments
Category Value
Study start date 2010-08-09

View full details